Accepted answer
The part that matters: a certificate that reports one test result on one vial extrapolates to claim that all two hundred vials in the lot are identical, which is an assumption worth questioning.
If you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.
What each test answers
| Test | Answers | Does NOT answer |
|---|
| RP-HPLC, area % | What fraction of detected material is the target | How much target is present |
| Quantified content | Milligrams of peptide per vial | What the impurities are |
| ESI-MS identity | Whether the molecular weight matches | Purity, or isomeric substitution |
| Peptide mapping | Sequence, localised to a fragment | Quantity |
| Karl Fischer | Water content of the solid | Solvent content |
| LAL endotoxin | Pyrogen load in EU/mg | Sterility |
| Sterility test | Growth in defined media over 14 days | Endotoxin, or bioburden count |
A statement that "lot 20260412 complies with specifications" is meaningless without stating which vials from the lot were tested and how many there were.
Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.
One qualification: testing more vials gives better confidence, but at some point the cost outweighs the benefit.
Assume segregation is possible, and design your sampling to catch it if it exists.
5This matches what I was told by a laboratory, for whatever that is worth. – Dr_Signe_Baldursdottir 8 months ago 4Minor: the trial name is hyphenated in the original publication. – harriet_lonsdale 6 months ago add a comment